Unknown

Dataset Information

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.


ABSTRACT: PLX4032/vemurafenib is a first-in-class small-molecule BRAF(V600E) inhibitor with clinical activity in patients with BRAF mutant melanoma. Nevertheless, drug resistance develops in treated patients, and strategies to overcome primary and acquired resistance are required. To explore the molecular mechanisms involved in primary resistance to PLX4032, we investigated its effects on cell proliferation and signaling in a panel of 27 genetically characterized patient-derived melanoma cell lines. Cell sensitivity to PLX4032 was dependent on BRAF(V600E) and independent from other gene alterations that commonly occur in melanoma such as PTEN loss, BRAF, and MITF gene amplification. Two cell lines lacking sensitivity to PLX4032 and harboring a different set of genetic alterations were studied as mod

SUBMITTER: Vergani E 

PROVIDER: S-EPMC3257188 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature